India, July 28 -- Shares of Celcuity Inc. (CELC) soared on Monday morning after reporting promising results from its Phase 3 trial, showing that its experimental drug gedatolisib, when combined with standard treatments, significantly extended progression-free survival (PFS) in patients with advanced hormone receptor-positive, HER2-negative, PIK3CA wild-type breast cancer.
CELC is currently trading at $38.00, up $24.23 or 175.96%, on a huge volume of 18 million shares, above the average volume of 208 thousand, on the Nasdaq. The stock opened its trading at $45.96 after closing Friday at $13.77. The stock has traded between $ 7.57 and $46.42 in the past 52-week period.
The data showed that the gedatolisib + fulvestrant + palbociclib (triple...